Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nektar Therapeutics 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 USA

www.nektar.com Employees: 61 P: 415-482-5300 F: 415-339-5300

Sector:

Medical

Description:

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.

Key Statistics

Overview:

Market Capitalization, $K 766,486
Enterprise Value, $K 722,236
Shares Outstanding, K 20,342
Float, K 19,274
% Float 94.75%
Short Interest, K 1,927
Short Float 9.48%
Days to Cover 3.31
Short Volume Ratio 0.62
% of Insider Shareholders 5.25%
% of Institutional Shareholders 75.88%

Financials:

Annual Sales, $ 98,430 K
Annual Net Income, $ -118,960 K
Last Quarter Sales, $ 11,790 K
Last Quarter Net Income, $ -35,520 K
EBIT, $ -138,480 K
EBITDA, $ -134,090 K

Growth:

1-Year Return 181.71%
3-Year Return 8.28%
5-Year Return -84.83%
5-Year Revenue Growth -14.12%
5-Year Earnings Growth 72.21%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.85 on 11/06/25
Next Earnings Date 03/11/26
Earnings Per Share ttm -10.35
EPS Growth vs. Prev Qtr 37.29%
EPS Growth vs. Prev Year 31.45%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 06/09/25

NKTR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -456.53%
Return-on-Assets % -57.80%
Profit Margin % -120.86%
Debt/Equity 0.00
Price/Sales 9.20
Price/Cash Flow N/A
Price/Book 7.90
Book Value/Share 4.47
Interest Coverage -3.24
60-Month Beta 1.31
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar